Arrowhead Pharmaceuticals, Inc.
Financials
Valuation Metrics
Arrowhead Pharmaceuticals, Inc.'s Market Cap is $12.12B. At end of 2025 it was $9.30B. Ranked #850 of 3,112 in US market (top 27%), #263 of 1,445 on NASDAQ (top 18%), #37 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 14%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $12.12B | US#850/3,112 Sec#37/269 |
| Revenue | $622M | US#2,232/3,112 Sec#71/269 |
| Net Income | $-301M | US—/3,112 Sec—/269 |
| Total Assets | $2.27B | US#1,992/3,112 Sec#52/269 |
| Net Assets | $614M | US#2,110/3,112 Sec#92/269 |
| Employees | 711 | US#1,313/3,112 Sec#42/269 |
| Value | ||
| P/B | 19.73x | US#2,809/3,112 Sec#233/269 |
| P/S | 19.48x | US#2,808/3,112 Sec#144/269 |
| FCF Yield | -0.42% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -49.01% | US#2,735/3,112 Sec#170/269 |
| ROA | -13.27% | US#2,695/3,112 Sec#110/269 |
| Op. Margin | -35.67% | US#2,745/3,112 Sec#110/269 |
| Revenue Growth | -86.41% | US#2,925/3,112 Sec#178/269 |
| Earnings Growth | -135.83% | US#2,149/3,112 Sec#70/269 |
| Financial Health | ||
| Debt Ratio | 271.89% | US#2,044/3,112 Sec#216/269 |
| Total Debt | $1.37B | US#1,319/3,112 Sec#35/269 |
| FCF | $-51M | US#2,465/3,112 Sec#113/269 |
| Cash | $189M | US#1,771/3,112 Sec#120/269 |
| Current Ratio | 6.23x | US#384/3,112 Sec#125/269 |
| Performance | ||
| 1Y Return | 439.92% | US#22/3,112 Sec#11/269 |
| 1M Return | 2.41% | US#1,291/3,112 Sec#54/269 |
| From 52W High | -9.93% | US#1,038/3,112 Sec#51/269 |
| 1Y MDD | -24.64% | US#1,012/3,112 Sec#55/269 |
| Trading | ||
| Volume | 1,245,194 shares | US#1,295/3,112 Sec#128/269 |
| Trading Value | $105M | US#873/3,112 Sec#52/269 |
| Per Share | ||
| EPS | $1.44 | US#1,457/3,112 Sec#50/269 |
| BPS | $4.06 | US#2,308/3,112 Sec#146/269 |
Company Info
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.